# D. Sholter

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/d-sholter/

## Facts

| Field | Value |
| --- | --- |
| Citations | 302 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 8 |
| i10-index | 7 |
| Last Known Institution | University of Alberta |
| OpenAlex ID | https://openalex.org/A5009712221 |
| Works | 38 |

## Researcher papers

- [Validity and reliability of the 6 minute walk in persons with fibromyalgia.](https://scholariq.org/papers/validity-and-reliability-of-the-6-minute-walk-in-persons-with-fibromyalgia/)
- [Relative urgency for referral from primary care to rheumatologists: The Priority Referral Score](https://scholariq.org/papers/relative-urgency-for-referral-from-primary-care-to-rheumatologists-the-priority/)
- [Yttrium-90 radiochemical synovectomy in chronic knee synovitis: a one year retrospective review of 133 treatment interventions.](https://scholariq.org/papers/yttrium-90-radiochemical-synovectomy-in-chronic-knee-synovitis-a-one-year/)
- [Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists: A National, Multicenter, Retrospective Cohort](https://scholariq.org/papers/early-management-of-newly-diagnosed-rheumatoid-arthritis-by-canadian/)
- [Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis](https://scholariq.org/papers/biologic-treatment-registry-across-canada-biotrac-a-multicentre-prospective/)
- [Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent](https://scholariq.org/papers/successful-switch-of-patients-with-rheumatoid-arthritis-developing-anti-tumor/)
- [Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry](https://scholariq.org/papers/long-term-effectiveness-and-safety-of-infliximab-golimumab-and-ustekinumab-in/)
- [Treating to Target(s) With Interleukin-17 Inhibitors](https://scholariq.org/papers/treating-to-target-s-with-interleukin-17-inhibitors/)
- [Radiochemical Synovectomy](https://scholariq.org/papers/radiochemical-synovectomy/)
- [Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials](https://scholariq.org/papers/maintenance-of-patient-reported-outcomes-in-baricitinib-treated-patients-with/)
- [Adoption and perception of LLM-based chatbots in health care: an exploratory cross-sectional survey of individuals with rheumatic diseases](https://scholariq.org/papers/adoption-and-perception-of-llm-based-chatbots-in-health-care-an-exploratory/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Researcher university

- [University of Alberta](https://scholariq.org/institutions/university-of-alberta/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.